Cited by 4,175Dementia and Cognitive Impairment ResearchPsychological Testing and AssessmentHistorical and Modern Theater Studies

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

A new rating scale for Alzheimer's disease

Wilma G. Rosen, Richard C. Mohs, Kenneth L. Davis·1984·American Journal of Psychiatry

DOI 10.1176/ajp.141.11.1356

Open this paper in CoChat — free account

Abstract

A new rating instrument, the Alzheimer's Disease Assessment Scale, was designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic of persons with Alzheimer's disease. Item descriptions, administration procedures, and scoring are outlined. Twenty-seven subjects with Alzheimer's disease and 28 normal elderly subjects were rated on 40 items. Twenty-one items with significant intraclass correlation coefficients for interrater reliability (range, .650-.989) and significant Spearman rank-order correlation coefficients for test-retest reliability (range, .514-1) constitute the final scale. Subjects with Alzheimer's disease had significantly more cognitive and noncognitive dysfunction than the normal elderly subjects.

Integrity signals

Registry

Crossref · 10.1176/ajp.141.11.1356

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects
Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117
Pathological verification of ischemic score in differentiation of dementias
Rosen, W. G., Terry, R. D., Fuld, P. A., Katzman, R., & Peck, A. (1980) · Annals of Neurology · doi:10.1002/ana.410070516 · Cited by 1,273
Self-citation
A New Scale for Clinical Assessment in Geriatric Populations: Sandoz Clinical Assessment – Geriatric (SCAG)*
Shader, R. I., Harmatz, J. S., & Salzman, C. (1974) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1974.tb01521.x · Cited by 307
Effects of Naloxone in Senile Dementia: A Double-Blind Trial
Reisberg, ‌., Ferris, S. H., Anand, R., Mir, P., Geibel, V., de Leon, M. J., & Roberts, E. R. (1983) · New England Journal of Medicine · doi:10.1056/nejm198303243081213 · Cited by 151
RELIABILITY AND VALIDITY OF A SCALE FOR ASSESSING THE FUNCTIONING OF GERIATRIC PATIENTS
Plutchik, R., Conte, H. R., Lieberman, M., Bakur, M., Grossman, J., & Lehrman, N. S. (1970) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1970.tb01335.x · Cited by 114
ALZHEIMERʼS DISEASE
Sim, M., & Sussman, I. (1962) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196212000-00002 · Cited by 113
Apomorphine and Other Dopaminomimetics: Basic Pharmacology, Vol. I
Davis, G. C. (1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.6.838 · Cited by 109
A Brief Psychogeriatric Assessment Schedule
Pattie, A. H., & Gilleard, C. J. (1975) · The British Journal of Psychiatry · doi:10.1192/bjp.127.5.489 · Cited by 101
Clinical Value of the London Psychogeriatric Rating Scale
Hersch, E. L., Kral, V. A., & Palmer, R. (1978) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1978.tb03682.x · Cited by 100
Enhancement of Memory by Physostigmine
(1979) · New England Journal of Medicine · doi:10.1056/nejm197910253011721 · Cited by 99

Show all 19 references

Research works printed but not linked: 14

Salzman C, 1972, Kochansky GE
Reisberg B, 1983, The Brief Cognitive Rating Scale (BCRS): findings in primary degenerative dementia (PDD). Psychopharmacol Bull 19: 47-SO
Cole MG, 1980, Journal of Clinical and Experimental Gerontology, 2, 46
Mohs RC, 1982, Rosen WG
Corsellis JAN, 1962, Mental Illness and the Aging Brain
Coblentz JM, 1973, Presenile dementia: clinical aspects and evaluation of cerebrospinal fluid dynamics. Arch Neurol 29:299-308
Ajuriaguerra Jd R, 1980, Ciompi L. Berne, Hans Huber
Mayer-Gross W, 1969, Roth M: Clinical Psychiatry
Rosen WG, 1982, Alzheimer's Disease: A Report of Progress in Research. Edited by Corkin 5, Davis KL, Growdon JH, et al.
Goodglass H, 1972, Kaplan E: The Assessment of Aphasia and Related Disorders
Thorndike EL, 1944, Lorge I: The Teacher's Word Book of 30,000 Words
Wells CE, 1977, FA Davis
Guilford JP, 1978, Fruchter B: Fundamental Statistics in Psychology and Education
Davis KL, 1982, Psychopharmacol Bull, 18, 193

Sorted by citations

Items 201–269 of 269

A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia
Wang, T., Kuang, W., Chen, W., Xu, W., Zhang, L., Li, Y., Li, H., Peng, Y., Chen, Y., Wang, B., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00678-3 · Cited by 103
Deep Brain Stimulation Targeting the Fornix for Mild Alzheimer Dementia (the ADvance Trial): A Two Year Follow-up Including Results of Delayed Activation
Leoutsakos, J.-M. S., Yan, H., Anderson, W. S., Asaad, W. F., Baltuch, G., Burke, A., Chakravarty, M. M., Drake, K. E., Foote, K. D., Fosdick, L., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180121 · Cited by 104
Diffusion MRI Indices and Their Relation to Cognitive Impairment in Brain Aging: The Updated Multi-protocol Approach in ADNI3
Zavaliangos-Petropulu, A., Nir, T. M., Thomopoulos, S. I., Reid, R. I., Bernstein, M. A., Borowski, B., Jack Jr., C. R., Weiner, M. W., Jahanshad, N., & Thompson, P. M. (2019) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2019.00002 · Cited by 101
“The ADAS-cog is frequently used in pharmaceutical trials, with scores ranging from 0 to 70; higher scores represent more severe cognitive dysfunction (Rosen et al., 1984).”
Aerobic and strength training exercise programme for cognitive impairment in people with mild to moderate dementia: the DAPA RCT
Lamb, S. E., Mistry, D., Alleyne, S., Atherton, N., Brown, D., Copsey, B., Dosanjh, S., Finnegan, S., Fordham, B., Griffiths, F., et al. (2018) · Health Technology Assessment · doi:10.3310/hta22280 · Cited by 98
“The primary outcome was the global cognition score of the Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-Cog).(70) The funder’s brief was clear that the primary purpose of the trial and of the exercise programme should be to determine whether or not exercise can modify cognitive functioning.”
Method
Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment
Weise, C. M., Chen, K., Chen, Y., Kuang, X., Savage, C. R., & Reiman, E. M. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.07.016 · Cited by 96
Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer’s Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial
Boada, M., Anaya, F., Ortiz, P., Olazarán, J., Shua-Haim, J. R., Obisesan, T. O., Hernández, I., Muñoz, J., Buendia, M., Alegret, M., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160565 · Cited by 94
The ADAS-Cog revisited: Novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials
Raghavan, N., Samtani, M. N., Farnum, M., Yang, E., Novak, G., Grundman, M., Narayan, V., DiBernardo, A., & Initiative, A. D. N. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.05.2187 · Cited by 96
Impact of multisession 40Hz tACS on hippocampal perfusion in patients with Alzheimer’s disease
Sprugnoli, G., Munsch, F., Cappon, D., Paciorek, R., Macone, J., Connor, A., El Fakhri, G., Salvador, R., Ruffini, G., Donohoe, K., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00922-4 · Cited by 99
Associations of White Matter Hyperintensities with Cognitive Decline: A Longitudinal Study
Wang, Y.-L., Chen, W., Cai, W.-J., Hu, H., Xu, W., Wang, Z.-T., Cao, X.-P., Tan, L., Yu, J.-T., & Initiative, A. D. N. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-191005 · Cited by 92
Fine-mapping of the human leukocyte antigen locus as a risk factor for Alzheimer disease: A case–control study
Steele, N. Z. R., Carr, J. S., Bonham, L. W., Geier, E. G., Damotte, V., Miller, Z. A., Desikan, R. S., Boehme, K. L., Mukherjee, S., Crane, P. K., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002272 · Cited by 91
The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease
Hadjichrysanthou, C., Evans, S., Bajaj, S., Siakallis, L. C., McRae-McKee, K., de Wolf, F., Anderson, R. M., & Initiative, T. A. D. N. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00636-z · Cited by 86
“…as AD and dementia indicators: the ADAS-Cog 11 (ranged from 0 to 70, with the first number being the least severe and the last the most severe [27]) and the ADAS-Cog 13 (0 to 85) [28]; the Mini-Mental State Examination (MMSE) test (30 to 0) [29] which is an indicator of mental status; the…”
Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress
Boada, M., López, O., Núñez, L., Szczepiorkowski, Z. M., Torres, M., Grifols, C., & Páez, A. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.01.001 · Cited by 91
Blood Pressure Variability and Progression of Clinical Alzheimer Disease
de Heus, R. A. A., Olde Rikkert, M. G. M., Tully, P. J., Lawlor, B. A., Claassen, J. A. H. R., & for the NILVAD Study Group (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13664 · Cited by 88
Education and APOE-e4 in Longitudinal Cognitive Decline: MacArthur Studies of Successful Aging
Seeman, T. E., Huang, M.-H., Bretsky, P., Crimmins, E., Launer, L., & Guralnik, J. M. (2005) · The Journals of Gerontology Series B: Psychological Sciences and Social Sciences · doi:10.1093/geronb/60.2.p74 · Cited by 88
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Wattmo, C., Blennow, K., & Hansson, O. (2020) · BMC Neurology · doi:10.1186/s12883-019-1591-0 · Cited by 93
Use of Antioxidant Supplements and Its Association with Cognitive Function in a Rural Elderly Cohort: The MoVIES Project
Mendelsohn, A. B., Belle, S. H., Stoehr, G. P., & Ganguli, M. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009556 · Cited by 88
Age and Rate of Cognitive Decline in Alzheimer Disease: Implications for Clinical Trials
Bernick, C., Cummings, J., Raman, R., Sun, X., & Aisen, P. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3758 · Cited by 85
Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting
Wallin, Å. K., Andreasen, N., Eriksson, S., Båtsman, S., Näsman, B., Ekdahl, A., Kilander, L., Grut, M., Rydén, M., Wallin, A., et al. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000098052 · Cited by 84
Openness to experience, intelligence, and successful ageing
Gregory, T., Nettelbeck, T., & Wilson, C. (2010) · Personality and Individual Differences · doi:10.1016/j.paid.2010.02.017 · Cited by 81
Suspected non-AD pathology in mild cognitive impairment
Wisse, L. E. M., Butala, N., Das, S. R., Davatzikos, C., Dickerson, B. C., Vaishnavi, S. N., Yushkevich, P. A., & Wolk, D. A. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.029 · Cited by 78
The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer’s disease: A Bayesian network meta-analysis
Kobayashi, H., Ohnishi, T., Nakagawa, R., & Yoshizawa, K. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4405 · Cited by 79
Maternal family history is associated with Alzheimer's disease biomarkers
Honea, R. A., Initiative, F. T. A. D. N., Vidoni, E. D., Swerdlow, R. H., & Burns, J. M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120676 · Cited by 79
Midlife homocysteine and late-life dementia in women. A prospective population study
Zylberstein, D. E., Lissner, L., Björkelund, C., Mehlig, K., Thelle, D. S., Gustafson, D., Östling, S., Waern, M., Guo, X., & Skoog, I. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.02.024 · Cited by 76
Participation in dementia research: rates and correlates of capacity to give informed consent: Table 1
Warner, J., McCarney, R., Griffin, M., Hill, K., & Fisher, P. (2008) · Journal of Medical Ethics · doi:10.1136/jme.2006.019786 · Cited by 75
Meaningful benefits: A framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Assunção, S. S., Sperling, R. A., Ritchie, C., Kerwin, D. R., Aisen, P. S., Lansdall, C., Atri, A., & Cummings, J. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00984-y · Cited by 71
Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease
Burns, A., Gauthier, S., & Perdomo, C. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1746 · Cited by 71
Psychosis in Alzheimer's disease is associated with frontal metabolic impairment and accelerated decline in working memory: findings from the Alzheimer's Disease Neuroimaging Initiative
Koppel, J., Sunday, S., Goldberg, T. E., Davies, P., Christen, E., & Greenwald, B. S. (2014) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2012.10.028 · Cited by 65
Apathy as a feature of prodromal Alzheimer's disease: an FDG-PET ADNI study
Delrieu, J., Desmidt, T., Camus, V., Sourdet, S., Boutoleau‐Bretonnière, C., Mullin, E., Vellas, B., Payoux, P., Lebouvier, T., & Initiative, A. D. N. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4161 · Cited by 66
Accurate risk estimation of β‐amyloid positivity to identify prodromal Alzheimer's disease: Cross‐validation study of practical algorithms
Palmqvist, S., Insel, P. S., Zetterberg, H., Blennow, K., Brix, B., Stomrud, E., Initiative, T. A. D. N., study, T. S. B., Mattsson, N., & Hansson, O. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.014 · Cited by 65
Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairment
Liu-Ambrose, T., Eng, J. J., Boyd, L. A., Jacova, C., Davis, J. C., Bryan, S., Lee, P., Brasher, P., & Hsiung, G.-Y. R. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-14 · Cited by 64
Long-term progression of Alzheimer's disease in patients under antidementia drugs
Gillette‐Guyonnet, S., Andrieu, S., Nourhashemi, F., Gardette, V., Coley, N., Cantet, C., Gauthier, S., Ousset, P., Vellas, B., & REAL.FR study group (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.02.009 · Cited by 64
Cognitive Response to Memantine in Moderate to Severe Alzheimer Disease Patients Already Receiving Donepezil: An Exploratory Reanalysis
Schmitt, F. A., van Dyck, C. H., Wichems, C. H., & Olin, J. T. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213860.35355.d4 · Cited by 62
Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative
Grill, J. D., Di, L., Lu, P. H., Lee, C., Ringman, J., Apostolova, L. G., Chow, N., Kohannim, O., Cummings, J. L., Thompson, P. M., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.03.006 · Cited by 58
Prevalence of obstructive sleep apnea in Alzheimer’s disease patients
Gaeta, A. M., Benítez, I. D., Jorge, C., Torres, G., Dakterzada, F., Minguez, O., Huerto, R., Pujol, M., Carnes, A., Dalmases, M., et al. (2020) · Journal of Neurology · doi:10.1007/s00415-019-09668-4 · Cited by 55
Effects of a 6-Month Cognitive Intervention on Brain Metabolism in Patients with Amnestic MCI and Mild Alzheimer's Disease
Förster, S., Buschert, V. C., Teipel, S. J., Friese, U., Buchholz, H.-G., Drzezga, A., Hampel, H., Bartenstein, P., & Buerger, K. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-0025 · Cited by 54
Efficacy of cognitive stimulation therapy for older adults with vascular dementia
Piras, F., Carbone, E., Faggian, S., Salvalaio, E., Gardini, S., & Borella, E. (2017) · Dementia & Neuropsychologia · doi:10.1590/1980-57642016dn11-040014 · Cited by 54
Cognitive effects of a dietary supplement made from extract of Bacopa monnieri, astaxanthin, phosphatidylserine, and vitamin E in subjects with mild cognitive impairment: A noncomparative, exploratory clinical study
Zanotta, D., Puricelli, S., & Bonoldi, G. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s51092 · Cited by 54
Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease
Trzepacz, P. T., Cummings, J., Konechnik, T., Forrester, T. D., Chang, C., Dennehy, E. B., Willis, B. A., Shuler, C., Tabas, L. B., & Lyketsos, C. (2013) · International Psychogeriatrics · doi:10.1017/s1041610212002141 · Cited by 53
Longitudinal Progression of Cognitive Decline Correlates with Changes in the Spatial Pattern of Brain 18 F-FDG PET
Shokouhi, S., Claassen, D., Kang, H., Ding, Z., Rogers, B., Mishra, A., Riddle, W. R., & Initiative, F. T. A. D. N. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.116137 · Cited by 54
“The ADAS_cog has a total score range from 0 of 70 points to measure the severity of cognitive impairment and is widely used in AD clinical trials (22).”
Method
Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting
Wallin, Å., Minthon, & Wattmo, C. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s24196 · Cited by 50
Detecting effects of donepezil on visual selective attention using signal detection parameters in Alzheimer's disease
Foldi, N. S., White, R. E. C., & Schaefer, L. A. (2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1319 · Cited by 51
Recommendations for ICT use in Alzheimer's disease assessment: Monaco CTAD expert meeting
Robert, P. H., Konig, A., Andrieu, S., Bremond, F., Chemin, I., Chung, P. C., Dartigues, J. F., Dubois, B., Feutren, G., Guillemaud, R., et al. (2013) · The Journal of nutrition, health and aging · doi:10.1007/s12603-013-0046-3 · Cited by 46
Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls
Mattsson, N., Insel, P. S., Donohue, M., Jagust, W., Sperling, R., Aisen, P., & Weiner, M. W. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4530 · Cited by 45
The Cambridge behavioral inventory: validation and application in a memory clinic
Nagahama, Y., Okina, T., Suzuki, N., & Matsuda, M. (2006) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988706286545 · Cited by 45
Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy
Wallin, Å. K., Gustafson, L., Sjögren, M., Wattmo, C., & Minthon, L. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000079201 · Cited by 45
Inter-individual differences in the responses to aerobic exercise in Alzheimer’s disease: Findings from the FIT-AD trial
Yu, F., Salisbury, D., & Mathiason, M. A. (2021) · Journal of Sport and Health Science · doi:10.1016/j.jshs.2020.05.007 · Cited by 40
“The test was deemed a maximal test when meeting at least two of the following criteria: (a) HR 90% of the age-predicted maximum HR, (b) RPE 17/20, (c) no increase in oxygen consumption with increasing exercise intensity, or (d) respiratory exchange ratio 1.1.36 Cognition was measured by the ADAS-Cog.37 The ADASCog ass…”
MethodInfluential
Three sides of the same coin: Measuring global cognitive impairment with the MMSE, ADAS‐cog and CAMCOG
Wouters, H., van Gool, W. A., Schmand, B., Zwinderman, A. H., & Lindeboom, R. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2402 · Cited by 43
Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort
Aguilar, C., Muehlboeck, J.-S., Mecocci, P., Vellas, B., Tsolaki, M., Kloszewska, I., Soininen, H., Lovestone, S., Wahlund, L.-O., Simmons, A., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00145 · Cited by 34
The Rationale and Design of the Reducing Pathology in Alzheimer’s Disease through Angiotensin TaRgeting (RADAR) Trial
Kehoe, P. G., Blair, P. S., Howden, B., Thomas, D. L., Malone, I. B., Horwood, J., Clement, C., Selman, L. E., Baber, H., Lane, A., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170101 · Cited by 35
Intepirdine as adjunctive therapy to donepezil for mild‐to‐moderate Alzheimer's disease: A randomized, placebo‐controlled, phase 3 clinical trial (MINDSET)
Lang, F. M., Mo, Y., Sabbagh, M., Solomon, P., Boada, M., Jones, R. W., Frisoni, G. B., Grimmer, T., Dubois, B., Harnett, M., et al. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12136 · Cited by 34
The ADNI PET core at 20
Jagust, W. J., Koeppe, R. A., Rabinovici, G. D., Villemagne, V. L., Harrison, T. M., Landau, S. M., & Initiative, T. A. D. N. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14165 · Cited by 34
Prediction of progression from mild cognitive impairment to Alzheimer's disease with longitudinal and multimodal data
Ding, H., Wang, B., Hamel, A. P., Melkonyan, M., Ang, T. F. A., Au, R., & Lin, H. (2023) · Frontiers in Dementia · doi:10.3389/frdem.2023.1271680 · Cited by 32
DunedinPACNI estimates the longitudinal pace of aging from a single brain image to track health and disease
Whitman, E. T., Elliott, M. L., Knodt, A. R., Abraham, W. C., Anderson, T. J., Cutfield, N. J., Hogan, S., Ireland, D., Melzer, T. R., Ramrakha, S., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00897-z · Cited by 37
White-matter lesions without lacunar infarcts in CADASIL
Benisty, S., Reyes, S., Godin, O., Hervé, D., Zieren, N., Jouvent, E., Zhu, Y., During, M., Dichgans, M., & Chabriat, H. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111784 · Cited by 30
Effects of lacunar infarctions on cognitive impairment in patients with cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy
Lee, J. S., Choi, J. C., Kang, S.-Y., Kang, J.-H., Na, H. R., & Park, J.-K. (2011) · Journal of Clinical Neurology · doi:10.3988/jcn.2011.7.4.210 · Cited by 30
Effect of masupirdine (SUVN‐502) on cognition in patients with moderate Alzheimer's disease: A randomized, double‐blind, phase 2, proof‐of‐concept study
Nirogi, R., Ieni, J., Goyal, V. K., Ravula, J., Jetta, S., Shinde, A., Jayarajan, P., Benade, V., Palacharla, V. R. C., Dogiparti, D. K., et al. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12307 · Cited by 29
Lanabecestat: Neuroimaging results in early symptomatic Alzheimer’s disease
Zimmer, J. A., Shcherbinin, S., Devous, M. D., Bragg, S. M., Selzler, K. J., Wessels, A. M., Shering, C., Mullen, J., Landry, J., Andersen, S. W., et al. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12123 · Cited by 27
Improving medication adherence among community-dwelling seniors with cognitive impairment: a systematic review of interventions
Kröger, E., Tatar, O., Vedel, I., Giguère, A. M. C., Voyer, P., Guillaumie, L., Grégoire, J.-P., & Guénette, L. (2017) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-017-0487-6 · Cited by 23
Alzheimer's Residents' Cognitive and Functional Measures: Special and Traditional Care Unit Comparison
Swanson, E. A., Maas, M. L., & Buckwalter, K. C. (1994) · Clinical Nursing Research · doi:10.1177/105477389400300104 · Cited by 25
Sleep-Disordered Breathing in Hospitalized Geriatric Patients with Mild Dementia and Its Association with Cognition, Emotion and Mobility
Gronewold, J., Haensel, R., Kleinschnitz, C., Frohnhofen, H., & Hermann, D. M. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16050863 · Cited by 23
A Longitudinal Study of Transitions Between Informal and Formal Care in Alzheimer Disease Using Multistate Models in the European ICTUS Cohort
Coley, N., Gallini, A., Garès, V., Gardette, V., Andrieu, S., Vellas, B., Reynish, E., Ousset, P. J., Andrieu, S., Burns, A., et al. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.09.010 · Cited by 20
Machine learning models identify predictive features of patient mortality across dementia types
Zhang, J., Song, L., Miller, Z., Chan, K. C. G., & Huang, K.-L. (2024) · Communications Medicine · doi:10.1038/s43856-024-00437-7 · Cited by 20
Targeting amyloid β in Alzheimer’s disease: Meta-analysis of low-dose solanezumab in Alzheimer’s disease with mild dementia studies
Holdridge, K. C., Yaari, R., Hoban, D. B., Andersen, S., & Sims, J. R. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13031 · Cited by 19
Assessing Alzheimer’s disease from speech using the i-vector approach
Egas López, J. V., Tóth, L., Hoffmann, I., Kálmán, J., Pákáski, M., & Gosztolya, G. (2019) · Lecture notes in computer science · doi:10.1007/978-3-030-26061-3_30 · Cited by 18
Subjective Memory Impairment and Gait Variability in Cognitively Healthy Individuals: Results from a Cross-Sectional Pilot Study
Beauchet, O., Launay, C. P., Chabot, J., Levinoff, E. J., & Allali, G. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160604 · Cited by 15
Mechanism of action and clinical trial results of Lecanemab (Leqembi® 200 ‍mg, 500 ‍mg for Intravenous Infusion), a novel treatment for Alzheimer’s disease
Niidome, T., Ishikawa, Y., Ogawa, T., Nakagawa, M., & Nakamura, Y. (2024) · Folia Pharmacologica Japonica · doi:10.1254/fpj.24005 · Cited by 14
Neurocognitive effects associated with proprotein convertase subtilisin-kexin type 9 inhibitor use: A narrative review
Yuet, W. C., Ebert, D., & Jann, M. (2021) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620959271 · Cited by 8
Artificial Intelligence, Speech, and Language Processing Approaches to Monitoring Alzheimer’s Disease: A Systematic Review
de la Fuente Garcia, S., Ritchie, C. W., & Luz, S. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200888 · Cited by 5
Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression: A Randomized Controlled Trial
Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Self-citation

Authors: Rosen, W. G., Mohs, R. C., & Davis, K. L.
Affiliations: James J. Peters VA Medical Center (US)
ORCID: Richard C. Mohs
Kenneth L. Davis
Venue: American Journal of Psychiatry
Publisher: American Psychiatric Association Publishing
Published: 1984-11-01
Volume: 141
Issue: 11
Pages: 1356-1364
ISSN: 0002-953X (ISSN-L)
1535-7228
DOI: 10.1176/ajp.141.11.1356
OpenAlex: W1953027527
Cited by: 4,175
References: 19
Citations by year: 2026: 111 · 2025: 129 · 2024: 171 · 2023: 139 · 2022: 149 · 2021: 180 · 2020: 167 · 2019: 149 · 2018: 165 · 2017: 150 · 2016: 129 · 2015: 149 · 2014: 157 · 2013: 160 · 2012: 141
FWCI: 10.05
Type: journal article
Language: en
Open access: closed
Locations: American Journal of Psychiatry (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Social Sciences › Psychology › Applied Psychology › Psychological Testing and Assessment
Social Sciences › Psychology › Clinical Psychology › Historical and Modern Theater Studies
Keywords: Alzheimer's disease, Alzheimer's Disease Assessment Scale, rating scale development, cognitive impairment, behavioral dysfunction, disease severity assessment, inter-rater reliability, test-retest reliability, elderly subjects
MeSH terms: Aged, Alzheimer Disease, Cognition Disorders, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Psychometrics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A new rating scale for Alzheimer's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks